Overview

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Sunovion
Treatments:
Albuterol